Literature DB >> 35873183

Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.

Sarath Lal Mannumbeth Renjithlal1, Mohamed Magdi1, Keerthi Renjith2, Mostafa Reda Mostafa1, Musaib Syed3, Fahd Shaukat1, Viqarunnisa Zahid4, Nathan Ritter4.   

Abstract

BACKGROUND: Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use.
METHODS: We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis.
RESULTS: Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients).
CONCLUSION: At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost. AJCD
Copyright © 2022.

Entities:  

Keywords:  Ticagrelor; acute coronary syndrome; clopidogrel; dual antiplatelet therapy; medication compliance/adherence; percutaneous coronary intervention

Year:  2022        PMID: 35873183      PMCID: PMC9301028     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  16 in total

1.  Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience.

Authors:  Thomas O Bergmeijer; Paul W A Janssen; Mathijs van Oevelen; Dymphie van Rooijen; Thea C Godschalk; Johannes C Kelder; Vera H M Deneer; Victor L Serebruany; Jurriën M Ten Berg
Journal:  Cardiology       Date:  2017-07-12       Impact factor: 1.869

2.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

3.  Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.

Authors:  Sara Ariotti; Luis Ortega-Paz; Maarten van Leeuwen; Salvatore Brugaletta; Sergio Leonardi; K Martijn Akkerhuis; Stefano F Rimoldi; Gladys Janssens; Umberto Gianni; Jan C van den Berge; Alexios Karagiannis; Stephan Windecker; Marco Valgimigli
Journal:  JACC Cardiovasc Interv       Date:  2018-05-24       Impact factor: 11.195

4.  Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.

Authors:  Robert F Storey; Richard C Becker; Robert A Harrington; Steen Husted; Stefan K James; Frank Cools; Philippe Gabriel Steg; Nardev S Khurmi; Håkan Emanuelsson; Anna Cooper; Richard Cairns; Christopher P Cannon; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-07-30       Impact factor: 29.983

5.  Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.

Authors:  Elisabet Nikolic; Magnus Janzon; Ole Hauch; Lars Wallentin; Martin Henriksson
Journal:  Eur Heart J       Date:  2012-06-19       Impact factor: 29.983

6.  Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.

Authors:  B Aleil; C Ravanat; J P Cazenave; G Rochoux; A Heitz; C Gachet
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

7.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

8.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kathleen Butler; Udaya S Tantry; Tania Gesheff; Cheryl Wei; Renli Teng; Mark J Antonino; Shankar B Patil; Arun Karunakaran; Dean J Kereiakes; Cordel Parris; Drew Purdy; Vance Wilson; Gary S Ledley; Robert F Storey
Journal:  Circulation       Date:  2009-11-18       Impact factor: 29.690

9.  Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Authors:  Seng Chan You; Yeunsook Rho; Behnood Bikdeli; Jiwoo Kim; Anastasios Siapos; James Weaver; Ajit Londhe; Jaehyeong Cho; Jimyung Park; Martijn Schuemie; Marc A Suchard; David Madigan; George Hripcsak; Aakriti Gupta; Christian G Reich; Patrick B Ryan; Rae Woong Park; Harlan M Krumholz
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

Review 10.  Dyspnoea management in acute coronary syndrome patients treated with ticagrelor.

Authors:  Guido Parodi; Robert F Storey
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2014-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.